{"id":62902,"date":"2026-04-07T22:02:28","date_gmt":"2026-04-07T20:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/"},"modified":"2026-04-07T22:02:28","modified_gmt":"2026-04-07T20:02:28","slug":"intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/","title":{"rendered":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch"},"content":{"rendered":"
\n

\nCases include patients who failed prior treatment attempts for in-stent restenosis and native vessel obstructions<\/b><\/p>\n

REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana\u00ae Thrombectomy Catheter System. The cases were performed across the company\u2019s limited US market release and its European first-in-human study.<\/p>\n

<\/a>
<\/a><\/p>\n

\n“We\u2019ve had the privilege of partnering with some of the most experienced and knowledgeable physicians to reach this important milestone,\u201d said Jeff Elkins, Chief Executive Officer of InterVene, Inc. \u201cWe are grateful for their support as we work to deliver purpose-built innovation for difficult-to-treat venous conditions.\u201d<\/p>\n

\nRecana is the first fully integrated mechanical thrombectomy system to receive US Food and Drug Administration (FDA) 510(k) clearance for the treatment of venous in-stent restenosis (ISR) and residual venous obstructions in native veins. The system features a stainless steel, helical debulking catheter, material collection baskets, and introducer and collection sheaths, designed to simplify complex venous procedures and improve clinical outcomes.<\/p>\n

\nISR and residual venous obstructions develop when a blood clot undergoes structural and composition changes that are resistant to traditional therapies.1<\/sup> As the vein lumen narrows, blood outflow from the legs is impaired, leading to venous hypertension. This condition is associated with symptoms such as persistent leg swelling, aching pain, skin discoloration, and, in severe cases, venous leg ulcers. In the United States, more than 25 million adults are affected by chronic venous insufficiency caused by venous obstruction, reflux, or both.2<\/sup><\/p>\n

\n\u201cIn-stent restenosis is a common complication following venous stenting,\u201d said Stephen Black, MD, Professor of Surgery, at Guy\u2019s and Thomas\u2019 Hospital, London. \u201cMany of these patients experience debilitating symptoms, but treatment is often limited to conservative care. My experience with Recana has fundamentally changed how I approach this disease.\u201d<\/p>\n

\n\u201cMillions of patients suffer from symptoms related to residual venous obstructions,\u201d said Mark Garcia, MD, FSIR, FACR, Wilmington, DE. \u201cThe Recana system shows promise as a new treatment option for native vessel obstructions.\u201d<\/p>\n

\nInterVene is currently conducting a limited US commercial release with select physicians specializing in ISR and residual venous obstructions. The company is also sponsoring prospective clinical studies in Galway, Ireland, led by Gerry O\u2019Sullivan, MD, and London, England, led by Stephen Black, MD.<\/p>\n

\nThe first 30 cases included patients having both ISR and native vessel obstructions, many of whom had experienced years of symptoms and multiple prior treatment attempts. InterVene plans to continue its limited market release as it prepares for a broader commercial launch later this year.<\/p>\n

\nAbout the Recana\u00ae Thrombectomy Catheter System<\/b><\/p>\n

\nRecana is the first fully integrated system cleared by the FDA for the treatment of venous in-stent restenosis (ISR) and residual native vessel obstructions. The system consists of a stainless steel, helical debulking catheter, material collection baskets, and introducer and collection sheaths. Recana is a purpose-built, standalone platform designed to simplify complex venous procedures and improve clinical outcomes.<\/p>\n

\nAbout InterVene, Inc.<\/b><\/p>\n

\nInterVene is a privately held medical technology company based in Redwood City, California. The company is focused on developing transformative products to treat the long-term complications of venous disease. Its flagship technology, the Recana\u00ae Thrombectomy Catheter System, is designed to treat venous in-stent restenosis and residual vein obstructions and occlusions, life-altering conditions that affect millions of people globally. InterVene is backed by RiverVest Venture Partners and Treo Ventures. For more information, visit www.intervene-med.com<\/a> and connect on LinkedIn<\/a>.<\/p>\n

\nReferences<\/b><\/p>\n

\n1. Saleem T, Raju S. An overview of in-stent restenosis in iliofemoral venous stents. J Vasc Surg Venous Lymphat Disord. 2022 Mar.<\/i><\/p>\n

\n2. Attaran RR, Edwards ML, Arena FJ, et al. 2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease: This statement was endorsed by the Society for Vascular Medicine (SVM). J Soc Cardiovasc Angiogr Interv. 2025 Jun.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
John Giesen
\n
Vice President, Marketing
\n
john@intervene-med.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Cases include patients who failed prior treatment attempts for in-stent restenosis and native vessel obstructions REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana\u00ae Thrombectomy Catheter System. The cases were performed across the company\u2019s limited US … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62902","6":"format-standard","7":"category-industry"},"yoast_head":"\nInterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Cases include patients who failed prior treatment attempts for in-stent restenosis and native vessel obstructions REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana\u00ae Thrombectomy Catheter System. The cases were performed across the company\u2019s limited US ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T20:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch\",\"datePublished\":\"2026-04-07T20:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/\"},\"wordCount\":653,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260407271477\\\/en\\\/2768003\\\/22\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/\",\"name\":\"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260407271477\\\/en\\\/2768003\\\/22\\\/Logo.jpg\",\"datePublished\":\"2026-04-07T20:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260407271477\\\/en\\\/2768003\\\/22\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260407271477\\\/en\\\/2768003\\\/22\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/","og_locale":"en_US","og_type":"article","og_title":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend","og_description":"Cases include patients who failed prior treatment attempts for in-stent restenosis and native vessel obstructions REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana\u00ae Thrombectomy Catheter System. The cases were performed across the company\u2019s limited US ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-07T20:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch","datePublished":"2026-04-07T20:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/"},"wordCount":653,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/","url":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/","name":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg","datePublished":"2026-04-07T20:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260407271477\/en\/2768003\/22\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/intervene-completes-first-30-cases-using-the-recana-thrombectomy-catheter-system-plans-for-broader-commercial-launch\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"InterVene Completes First 30 Cases Using the Recana\u00ae Thrombectomy Catheter System, Plans for Broader Commercial Launch"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62902"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62902\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}